Patents by Inventor Edward A. Ratovitski

Edward A. Ratovitski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • protein acts as an oncogene
    Patent number: 7468425
    Abstract: We have discovered p40, the shortest variant of a new human p53 homologue (p40/p51/p63/p73H). We have also found that it plays a role in cancer. Low level amplification of the p40 locus accompanied by RNA and protein overexpression was observed in primary lung cancers, and head and neck cancer cell lines. P40 protein overexpression in primary lung tumors was limited to squamous cell carcinoma, tumors known to harbor a high frequency of p53 mutations. Overexpression of p40 in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. We searched for p40 binding proteins using the yeast two-hybrid system. P53 was the most common binding target of the 1.6×106 clones screened from a mouse embryonic library. Moreover, coexpression of p40 and p53 led to a decrease in p53 transcriptional activity. Our results support the notion that p40 plays an oncogenic role in human cancer.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: December 23, 2008
    Assignee: The Johns Hopkins University
    Inventors: David Sidransky, Jin Jen, Barry Trink, Edward A. Ratovitski
  • P40 protein acts as an oncogene
    Publication number: 20030113774
    Abstract: We have discovered p40, the shortest variant of a new human p53 homologue (p40/p51/p63/p73H). We have also found that it plays a role in cancer. Low level amplification of the p40 locus accompanied by RNA and protein overexpression was observed in primary lung cancers, and head and neck cancer cell lines. P40 protein overexpression in primary lung tumors was limited to squamous cell carcinoma, tumors known to harbor a high frequency of p53 mutations. Overexpression of p40 in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. We searched for p40 binding proteins using the yeast two-hybrid system. P53 was the most common binding target of the 1.6×106 clones screened from a mouse embryonic library. Moreover, coexpression of p40 and p53 led to a decrease in p53 transcriptional activity. Our results support the notion that p40 plays an oncogenic role in human cancer.
    Type: Application
    Filed: October 22, 2002
    Publication date: June 19, 2003
    Applicant: The Johns Hopkins University
    Inventors: David Sidransky, Jin Jen, Barry Trink, Edward A. Ratovitski
  • p40 protein acts as an oncogene
    Patent number: 6476206
    Abstract: We have discovered p40, the shortest variant of a new human p53 homologue (p40/p51/p63/p73H). We have also found that it plays a role in cancer. Low level amplification of the p40 locus accompanied by RNA and protein overexpression was observed in primary lung cancers, and head and neck cancer cell lines. P40 protein overexpression in primary lung tumors was limited to squamous cell carcinoma, tumors known to harbor a high frequency of p53 mutations. Overexpression of p40 in Rat 1a cells led to an increase in soft agar growth and tumor size in mice. We searched for p40 binding proteins using the yeast two-hybrid system. P53 was the most common binding target of the 1.6×106 clones screened from a mouse embryonic library. Moreover, coexpression of p40 and p53 led to a decrease in p53 transcriptional activity. Our results support the notion that p40 plays an oncogenic role in human cancer.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: November 5, 2002
    Assignee: The Johns Hopkins University
    Inventors: David Sidransky, Jin Jen, Barry Trink, Edward A. Ratovitski
  • Soluble interferon .alpha.-receptor, its preparation and use
    Patent number: 5643749
    Abstract: New forms of interferon .alpha.-receptors are provided. They may be prepared recombinantly and may be used in diagnosis and therapy.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: July 1, 1997
    Assignee: Yeda Research and Development Co, Ltd.
    Inventors: Michel Revel, Carolina Abramovich, Edward Ratovitski